SXTCNasdaqPharmaceutical PreparationsFiscal year ends March 31

China SXT Pharmaceuticals, Inc.

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 1, 2026

$0.11+0.05 (+71.08%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

China SXT Pharmaceuticals, Inc. income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31	FY 2020 2020-03-31	FY 2019 2019-03-31	FY 2018 2018-03-31	FY 2017 2017-03-31
Revenue	1.14	1.74	1.93	1.97	2.60	4.78	5.16	7.01	7.02	4.88
Cost of Revenue	0.89	1.37	1.37	1.55	1.35	1.94	2.46	2.40	3.62	2.57
Gross Profit	0.25	0.37	0.55	0.43	1.25	2.84	2.70	4.61	3.40	2.31
Research & Development	–	–	0.18	0.20	0.37	–	–	–	–	–
Selling, General & Admin	7.37	3.05	3.07	6.03	6.44	5.04	–	–	–	–
Selling & Marketing	0.24	0.29	0.43	0.39	0.92	1.59	–	–	–	–
General & Administrative	7.13	2.76	2.64	5.65	5.52	3.45	2.46	1.24	1.26	0.57
Advertising Expenses	0.09	0.11	0.33	0.23	0.65	1.12	1.02	0.86	0.23	–
Operating Expenses	7.37	3.05	3.07	6.03	6.44	5.04	4.04	2.84	1.77	0.71
Operating Income	-7.12	-2.68	-2.52	-5.61	-5.19	-2.20	-1.34	1.77	1.63	1.60
Interest Expense	0.06	0.65	0.54	0.48	0.04	1.62	3.35	0.01	0.00	0.04
Other Non-Operating Income	0.92	-0.62	-0.58	-0.33	-0.22	-0.74	-9.05	0.02	0.00	-0.02
Asset Impairment Charges	–	1.01	0.40	0.35	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	0.07	–	–	–	–	–	–	–	–
Pretax Income	-6.21	-3.30	-3.10	-5.93	-5.41	-2.94	-10	1.79	1.63	1.58
Income Tax Expense	–	–	–	–	0.33	-0.19	-0.10	0.25	0.44	0.40
Net Income incl. Noncontrolling Interests	–	–	–	–	-5.74	-2.75	-10	1.54	–	–
Net Income	-6.21	-3.30	-3.10	-5.93	-5.74	-2.75	-10	1.54	1.19	1.19
EPS (Basic)(per share)	-9.13	-348.17	-4,285.66	-177.84	-137.92	-3.82	33.28	-0.30	0.24	0.24
EPS (Diluted)(per share)	-9.13	-348.17	-4,285.66	-177.84	-137.92	-3.82	1.66	-0.30	0.24	0.24
Shares Outstanding (Basic, Weighted)(shares)	0.68	0.01	0.00	0.03	0.04	0.72	0.31	5.14	5.00	5.00
Shares Outstanding (Diluted, Weighted)(shares)	0.68	0.01	0.00	0.03	0.04	0.72	6.18	5.14	5.00	5.00
EBITDA	-7.05	-2.60	-2.31	-5.36	-4.87	-1.85	-1.01	1.95	1.76	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2026

Profitability, FY2026

Gross margin: 21.9%
Operating margin: -625.9%
Net margin: -545.2%
Return on equity, FY2026: -27.5%

Financial strength

Current ratio: 7.93
Debt to equity: 0.03
Debt to assets: 2.9%
Cash to current liabilities: 647.8%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –